Trial Search Results

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cardiac stem cells (CSCs) both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

The University of Texas Health Science Center, Houston

Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Stanford Investigator(s):

Intervention(s):

  • Biological: Mesenchymal Stem Cells (MSC)
  • Biological: Cardiac Stem Cells (CSC)
  • Biological: Placebo (Plasmalyte A)

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   1. Be ≥ 21 and <80 years of age

   2. Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV
   dysfunction, and clinical evidence of HF

   3. Have a "detectable" area of myocardial injury defined as ≥ 5% LV involvement (infarct
   volume) and any subendocardial involvement by cMRI

   4. Have an EF ≤ 40% by cMRI

   5. Be receiving guideline‐driven medical therapy for heart failure at stable and
   tolerated doses for ≥ 1 month prior to consent. For beta‐blockade "stable" is defined
   as no greater than a 50% reduction in dose or no more than a 100% increase in dose.

   6. Be a candidate for cardiac catheterization

   7. Have NYHA class I, II, or III heart failure symptoms

   8. If a female of childbearing potential, be willing to use one form of birth control for
   the duration of the study, and undergo a pregnancy test at baseline and within 36
   hours prior to injection

Exclusion Criteria:

   1. Indication for standard-of-care surgery (including valve surgery, placement of
   left-ventricular assist device, or imminent heart transplantation), coronary artery
   bypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI) for
   the treatment of ischemic and/or valvular heart disease. Subjects who require or
   undergo PCI should undergo these procedures a minimum of 3 months in advance of
   randomization. Subjects who require or undergo CABG should undergo these procedures a
   minimum of 4 months in advance of randomization. In addition, subjects who develop a
   need for revascularization following enrollment should undergo revascularization
   without delay. Indication for imminent heart transplantation is defined as a high
   likelihood of transplant prior to collection of the 12 month study endpoint.
   Candidates cannot be UNOS status 1A or 1B, and they must have documented low
   probability of being transplanted

   2. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2)
   severe (any valve) insufficiency/regurgitation within 12 months of consent

   3. Aortic stenosis with valve area ≤ 1.5 cm2

   4. History of ischemic or hemorrhagic stroke within 90 days of consent

   5. History of a left ventricular remodeling surgical procedure utilizing prosthetic
   material

   6. Presence of a pacemaker and/or implantable cardioverter-defibrillator (ICD) generator
   with any of the following limitations/conditions:

      - manufactured before the year 2000

      - leads implanted < 6 weeks prior to consent

      - non-transvenous epicardial, or abandoned leads

      - subcutaneous ICDs

      - leadless pacemakers

      - any other condition that, in the judgment of device-trained staff, would deem an
      MRI contraindicated

   7. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD
   are not excluded)

   8. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to
   consent

   9. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)

10. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular
   fibrillation or ventricular tachycardia within 30 days of consent

11. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of
   consent, or symptomatic Mobitz II or higher degree atrioventricular block without a
   functioning pacemaker within 3 months of consent

12. Presence of LV thrombus

13. Evidence of active myocarditis

14. Baseline maximal oxygen consumption (VO2 max) greater than 75% of age and gender based
   predictive values

15. Baseline eGFR <35 ml/min/1.73m2

16. Blood glucose levels (HbA1c) >10%

17. Hematologic abnormality evidenced by hematocrit < 25%, white blood cell < 2,500/ul or
   platelet count < 100,000/ul

18. Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the upper limit of
   normal (ULN)

19. Coagulopathy (INR ≥ 1.3) not due to a reversible cause (e.g., warfarin and/or Factor
   Xa inhibitors). Subjects who cannot be withdrawn from anticoagulation will be
   excluded.

20. HIV and/or active hepatitis B virus (HBV) or hepatitis C virus (HCV)

21. Allergy to radiographic contrast material that cannot adequately be managed by
   premedication

22. Known history of anaphylactic reaction to penicillin or streptomycin

23. Received gene or cell-based therapy from any source within the previous 12 months

24. History of malignancy within 5 years (i.e., subjects with prior malignancy must be
   disease free for 5 years), excluding basal cell carcinoma and cervical carcinoma in
   situ which have been definitively treated

25. Condition that limits lifespan to < 1 year

26. History of drug abuse (illegal "street" drugs except marijuana, or prescription
   medications not being used appropriately for a pre-existing medical condition) or
   alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or
   legal problems arising from the use of alcohol or drugs within the past 24 months

27. Participation in an investigational therapeutic or device trial within 30 days of
   consent

28. Cognitive or language barriers that prohibit obtaining informed consent or any study
   elements

29. Pregnancy or lactation or plans to become pregnant in the next 12 months

30. Any other condition that, in the judgment of the Investigator or Sponsor, would impair
   enrollment, study product administration, or follow-up

Ages Eligible for Study

21 Years - 79 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Fouzia Khan
650-736-1410
Recruiting